Clearmind Medicine submits three international patent applications

Clearmind Medicine (CMND) announced that it has submitted three patent applications under the international Patent Cooperation Treaty, as part of its ongoing collaboration with SciSparc (SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system. The three patent applications refer to novel proprietary combinations of lysergic acid diethylamide, psilocybin, N,N-dimethyltryptamine and SciSparc’s Palmitoylethanolamide, the active ingredient of SciSparc’ proprietary CannAmide. These applications were previously filed as provisional patent applications with the United States Patent and Trademark Office. “Clearmind continues to be at the forefront of the psychedelic market with one of the largest IP portfolios in the industry. The PCT makes it possible for us to seek patent protection for our proprietary compounds in a large number of countries simultaneously which strengthens our IP portfolio. To date, our ongoing collaboration with SciSparc has led to the submission of 11 different patent applications, allowing us to continue to be at the forefront of research in the psychedelic industry while working on more effective and safer treatments,” said Clearmind’s Chief Executive Officer, Dr. Adi Zuloff-Shani.